Brendan Whelan

Title: Brendan Whelan: Innovator in Sodium Channel Inhibitors

Introduction

Brendan Whelan is a notable inventor based in Vancouver, Canada. He has made significant contributions to the field of pharmacology, particularly in the development of sodium channel inhibitors. With a total of 5 patents, his work focuses on compounds that address various medical conditions associated with voltage-gated ion channel function.

Latest Patents

Whelan's latest patents include innovative compounds that serve as benzimidazole inhibitors of the sodium channel. These compounds are particularly useful in treating conditions related to sodium channel activity. His research has led to the development of specific compounds that can be utilized in the treatment of a variety of diseases. Another significant patent involves heterocyclic inhibitors of the sodium channel, which are designed to treat conditions such as epilepsy, cancer, pain, migraine, Parkinson's Disease, mood disorders, schizophrenia, psychosis, tinnitus, amyotrophic lateral sclerosis, glaucoma, ischemia, spasticity disorders, obsessive-compulsive disorder, restless leg syndrome, and Tourette syndrome.

Career Highlights

Throughout his career, Whelan has worked with various companies, including Sumac Fabrication Company Ltd. His expertise in the field has allowed him to contribute to groundbreaking research and development in sodium channel inhibitors.

Collaborations

Whelan has collaborated with notable professionals in his field, including Hassan Pajouhesh and Richard James Holland. These collaborations have further enhanced his research and innovation in the area of pharmacology.

Conclusion

Brendan Whelan's contributions to the field of sodium channel inhibitors highlight his innovative spirit and dedication to improving medical treatments. His patents reflect a commitment to addressing complex health issues through scientific advancement.